Nationwide Fund Advisors Acquires 29,891 Shares of Acorda Therapeutics, Inc. (ACOR)

Nationwide Fund Advisors grew its holdings in Acorda Therapeutics, Inc. (NASDAQ:ACOR) by 25.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 146,207 shares of the biopharmaceutical company’s stock after buying an additional 29,891 shares during the period. Nationwide Fund Advisors owned 0.31% of Acorda Therapeutics worth $3,458,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC raised its position in shares of Acorda Therapeutics by 5.2% in the second quarter. FMR LLC now owns 6,998,913 shares of the biopharmaceutical company’s stock valued at $137,879,000 after buying an additional 348,895 shares during the last quarter. Vanguard Group Inc. increased its position in Acorda Therapeutics by 4.1% during the second quarter. Vanguard Group Inc. now owns 4,308,160 shares of the biopharmaceutical company’s stock worth $84,871,000 after purchasing an additional 168,571 shares during the last quarter. State Street Corp increased its position in Acorda Therapeutics by 52.4% during the second quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock worth $48,783,000 after purchasing an additional 851,290 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Acorda Therapeutics by 29.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock worth $46,745,000 after purchasing an additional 541,418 shares during the last quarter. Finally, RA Capital Management LLC increased its position in Acorda Therapeutics by 83.8% during the second quarter. RA Capital Management LLC now owns 900,259 shares of the biopharmaceutical company’s stock worth $17,735,000 after purchasing an additional 410,431 shares during the last quarter.

In other Acorda Therapeutics news, insider Burkhard Blank sold 11,050 shares of Acorda Therapeutics stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $20.53, for a total transaction of $226,856.50. Following the completion of the sale, the insider now directly owns 33,150 shares in the company, valued at $680,569.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.90% of the stock is owned by company insiders.

Several equities research analysts recently issued reports on ACOR shares. Cowen restated a “buy” rating and set a $35.00 price objective on shares of Acorda Therapeutics in a research report on Tuesday, August 29th. Stifel Nicolaus restated a “buy” rating and set a $26.00 price objective (down from $30.00) on shares of Acorda Therapeutics in a research report on Thursday, August 31st. HC Wainwright started coverage on shares of Acorda Therapeutics in a research report on Wednesday, November 8th. They set a “buy” rating and a $35.00 price objective for the company. TheStreet cut shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a research report on Friday, November 17th. Finally, J P Morgan Chase & Co set a $24.00 price objective on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, October 31st. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $21.47.

Shares of Acorda Therapeutics, Inc. (NASDAQ ACOR) opened at $21.05 on Monday. Acorda Therapeutics, Inc. has a 12-month low of $13.60 and a 12-month high of $33.00. The company has a current ratio of 2.77, a quick ratio of 2.40 and a debt-to-equity ratio of 0.49.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.26). Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The company had revenue of $141.07 million for the quarter, compared to analyst estimates of $150.64 million. During the same quarter in the prior year, the business earned ($0.04) earnings per share. Acorda Therapeutics’s revenue was up 4.0% on a year-over-year basis. equities analysts forecast that Acorda Therapeutics, Inc. will post -0.18 earnings per share for the current fiscal year.

WARNING: “Nationwide Fund Advisors Acquires 29,891 Shares of Acorda Therapeutics, Inc. (ACOR)” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/12/18/nationwide-fund-advisors-acquires-29891-shares-of-acorda-therapeutics-inc-acor.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply